Oniria Therapeutics receives €450,000 research grant from Spanish Association Against Cancer

Oniria Therapeutics is one of the 44 projects chosen by the Spanish Association Against Cancer (AECC) in Barcelona to receive a 2023 Research Grant for €450,000.

The AECC valued that Oniria Therapeutics is a biopharmaceutical spin-off created with the scientific excellence of the Vall d’Hebron Institute of Oncology (VHIO), University of Barcelona (UB) and Catalan Institution for Research and Advanced Studies (ICREA) that specializes in developing innovative drugs for precision oncology to eliminate persistent tumor cells.

In total, the AECC has given out €29.4 million in grants to 233 recipients all over Spain, 44 of which are in Barcelona. These grants aim to boost the average survival rate for people with cancer to 70% by 2030 and bring research results to patients.

The grant awarding ceremony was held yesterday at the AECC headquarters in Barcelona with Dr. Laureano Molins, president of the AECC in Barcelona, and Dr. Marta Puyol, scientific director at the Spanish Association Against Cancer Scientific Foundation, as well as other renowned researchers, spinoffs and patients.

“At the AECC in Barcelona we are working to raise awareness of our commitment to research. With these grants, we want to encourage our researchers’ talent and innovation and help oncology research projects become real treatments that can improve patients’ lives,” explained Dr. Laureano Molins.

“We are very happy to receive this grant to help us keep advancing our pipeline of drugs to activate the TET2 enzyme, which is the Achilles heel of persistent tumor cells and has been proven effective in animal models for colon cancer, melanoma and acute myeloid leukemia. The AECC supported us in starting Oniria in 2021 and is now again showing its confidence in our research based on precision oncology,” highlighted Oniria Therapeutics CEO and co-founder Esther Riambau.